Other baseline covariates (the presence of an apolipoprotein E ε4 allele, the presence of MCI, the number of chronic medical conditions, report of urinary incontinence, the number of depressive symptoms, the level of physical activity, or the presence of basic activities of daily living disability) did not modify the difference in the annual rate of cognitive decline before and after starting a medication with anticholinergic activity (Table S4). This evidence concerns the gene APOE and Mental deterioration.